Clinical trials in cardiac surgery

Blood Substitutes

Volumn , Issue , 2006, Pages 163-168

  Spahn, Donart R ^a   Chassot, Pierre Guy ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449107637     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012759760-7/50021-4     Document Type: Chapter

References (39)

1. Berson A.J., Smith J.M., Woods S.E., et al. Off-pump versus on-pump coronary artery bypass surgery: does the pump influence outcome?. J. Am. Coll. Surg. 2004, 199:102-108.
2. Bickell W.H., Wall M.J., Pepe P.E., et al. Immediate versus delayed flid resuscittion for hypotensive patients with penetrating torso injuries. N. Engl. J. Med. 1994, 331:1105-1109.
3. Chassot P.G., van der Linden P., Zaugg M., et al. Off-pump coronary artery bypass surgery: physiology and anaesthetic management. Br. J. Anaesth. 2004, 92:400-413.
4. Chatterjee R., Welty E.V., Walder R.Y., et al. Isolation and characterization of a new hemoglobin derivative crosslinked between the alpha chains (lysine 99 alpha 1 lysine 99 alpha 2). J. Biol. Chem. 1986, 261:9929-9937.
5. Cheng D.C. Safety and efficacy of o-raffinose crosslinked human hemoglobin (Hemolink) in cardiac surgery. Can. J. Anaesth. 2001, 48:S41-S48.
6. Cheng D.C., Mazer C.D., Martineau R., et al. A phase II dose-response study of hemoglobin raffimer (Hemolink) in elective coronary artery by pass surgery. J. Thorac. Cardiovasc. Surg. 2004, 127:79-86.
7. Frumento R.J., Monogero L.M., Naka Y., Bennett Guerrero E. Preserved gastric tonometric variables in cardiac surgical patients administered intravenous perflubron emulsion. Anesth. Analg. 2002, 94:809-814.
8. Greenburg A.G., Kim H.W. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery. J. Am. Coll. Surg. 2004, 198:373-384. Hemolink Study Group.
9. Hill S.E., Gottschalk L.I., Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary arterybypass surgery. J. Cardiothor. Vasc. Anesth. 2002, 16:659-702.
10. Hill S.E., Leone B.J., Faithfull N.S., et al. Perflubron emulsion (AF0144) augments harvesting of autologous blood: a phase II study in cardiac surgery. J. Cardiothor. Vasc. Anesth. 2002, 16:555-560.
11. Holman W.L., Spurell R.D., Ferguson E.R., et al. Tissue oxygenation with graded dissolved oxygen delivery during cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 1995, 110:774-785.
12. Keipert P.E. Perfluorochemical emulsions: future alternatives to transfusion. Blood Subst. Princ. Meth. Prod. Clin. Trials 1998, 2:127-156.
13. Keipert P.E., Gomez C.L., Gonzales A., et al. Diaspirin corsslinked hemoglobin: tissue distribution and long-term excretion after exchange transfusion. J. Lab. Clin. Med. 1994, 123:701-711.
14. Kerner T., Ahlers O., Veit S., et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European 'On-Scene' multicenter study. Intens Care Med. 2003, 29:378-385.
15. Krieter H., Hagen G., Waschke K.F., et al. Isovolemic hemodilution with a bovine hemoglobin based oxygen carrier: effects on hemodynamics and oxygen transport in comparison with a nonoxygen carrying volume substitute. J. Cardiothor. Vasc. Anesth. 1997, 11:3-9.
16. Lamy M.L., Daily E.K., Brichant J.-F., et al. Randomized trial of Diaspirin crosslinked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. Anesthesiology 2000, 92:646-656.
17. Leese P.T., Noveck J.J., Shorr J.S., et al. Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. Anesth. Analg. 2000, 91:804-811.
18. Levy J.H., Goodnough L.T., Greilich P.E., et al. Polymerized bovine hemoglobin solution as a replacement for alloganeic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J. Thorac. Cardiovasc. Surg. 2002, 124:35-42.
19. McGill N., O'Shaugnessy D., Pickering R., et al. Mechanical methods of reducing blood transfusion in cardiac surgery: rendomised controlled trial. Br. Med. J. 2002, 324:1299. erratum appears in Br. Med. J., 325(7356), 142.
20. TM in conscious, anaesthetized and treated spontaneously hypertensive rats. Transfus. Med. 2000, 10:13-27.
21. Ootaki Y., Yamaguchi M., Yoshimura N., et al. Efficiacy of a criterion-driven transfusion protocol in patients having pediatric cardiac surgery. J. Thorac. Cardiovasc. Surg. 2004, 127:953-958.
22. Porte R.J., Leebeek F.W. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002, 62:2193-2211.
23. Przybelski R.J., Daily E.K., Kisicki J.C. Phase I study of the safety and pharmacologic effects of diaspirin crosslinked hemoglobin solution. Crit Care Med. 1996, 24:1993-2000.
24. Puskas J.D., Williams W.H., Mahoney E.M., et al. Off-pump versus conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. J. Am. Med. Assoc. 2004, 291:1841-1849.
25. Riess J.G. Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomat. Artiuf. Cells Immob. Biotech. 1992, 20:183-202.
26. Riess J.G. Oxygen carriers ('blood substitutes')-raison d'etre, chemistry, and some physiology. Chem. Rev. 2001, 101:2797-2920.
27. Riess J.G., Keipert P.E. Blood Substitutes-Present and Future Perspectives 1998, 91-102. Elsevier Science, Lausanne. E. Tschida (Ed.).
28. Sloan E.P., Koenigsberg M., Gens D., et al. Diaspirin crosslinked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. J. Am. Med. Assoc. 1999, 282:1857-1864.
29. Sloan E.P., Koenigsberg M., Brunett P.H., et al. Post hoc mortality analysis of the efficacy trial of diaspirin crosslinked hemoglobin in the treatment of severe traumatic hemorrhagic shock. J. Trauma 2002, 52:887-895.
30. Spahn D.R., Leone B.J., Reves J.G., Pasch T. Cardiovascular and coronary physiology of acute isovolemic hemodilution: a review of nonoxygen-carrying and oxygen-carrying solutions. Anesth. Analg. 1994, 78:1000-1021.
31. Spahn D.R., van Bremt R., Theilmeier G., et al. Perflubron emulsion delays blood transfusion in orthopedic surgery. Anesthesiology 1999, 91:1195-1208.
32. Spahn D.R., Waschke K., Standl T., et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology 2002, 97:1338-1349.
33. Sprung J., Kindscher J.D., Wahr J.A., et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized single-blind study. Anesth. Anlag. 2002, 94:799-808.
34. Stowell C.P., Levin J., Spiess B.D., Winslow R.M. Progress in the development of rBC substitures. Transfusion 2001, 41:287-299.
35. Thurer R.L. Blood transfusion in cardiac surgery. Can. J. Anaesth. 2001, 48:S6-S12.
36. Vandegriff K.D., Medina F., Marini M.A., Winslow R.M. Equilibrium oxygen binding to human hemoglobin crosslinked between the alpha chains by bis(3,5-dibromosalicyl) fumarate. J. Biol. Chem. 1989, 264:17824-17833.
37. van der Linden P., De Hert S., Daper A., et al. A standardized multidisciplinary approach reduces the use of allogeneic blood products in patients undergoing cardiac surgery. Can. J. Anaesth. 2001, 48:894-901.
38. Wahr J.A., Trouwborst A., Spence R.K., et al. A pilot study of the effects of a perflubron emulsion, AF 0104, on mixed venous oxygen tesion in anesthetized surgical patients. Anesth. Analg. 1996, 82:103-107.
39. Winslow R.M. Current status of blood substitute research: towards a new paradigm. J. Intern. Med. 2003, 253:508-517.